Combivent vs. Salbutamol in Patients With Metacholine Induced Bronchospasm

Exclusion Criteria

• •Patients on treatment for or suspected as having glaucoma
• •Patients with known allergy of contra-indications to either salbutamol, ipratropium or their excipients
• •Patients suspected on clinical grounds to have pneumonia, pneumothorax or pneumomediastinum
• •Patients with a history of chest surgery
• •Patients with other respiratory conditions if diagnosed. These include pulmonary fibrosis, bronchiectasis, cystic fibrosis, sarcoidosis, pulmonary tuberculosis, pulmonary complications of AIDS
• •Patients requiring drugs for the treatment of the acute asthma attack other than the study drugs or oxygen
• •Patients who have been previously recruited into this study
• •Patients with myocardiopathy, pulmonary edema or other life threatening diseases, which in the judgement of the pediatrician precludes their entry into the study
• •Patients with obvious or previously diagnosed serious hepatic or renal disease
• •Patients who have been under the following drugs within the specified periods of time prior to determination of Baseline FEV1 or metacholine challenge
• •* INHALED:
• •* Short acting β2 agonists: 6 hours
• •* Long acting β2 agonists: 12 hours
• •* Ipratropium bromide: 8 hours
• •* DSCG (disodium cromoglicate): 7 days
• •* Nedocromil: 7 days
• •* ORAL:
• •* Short acting β2 agonists: 18 hours
• •* Anticholinergics: 7 days
• •* Short acting theophylline: 24 hours
• •* Long acting theophylline: 72 hours
• •* Antihistamines: 7 days
• •* Astemizole: 3 months
• •* Ketotifen: 3 months
• •* INHALED or ORAL: Other investigational drugs: 3 months
• •* INHALED or ORAL: Corticosteroids: 30 days